 |
148 Diseases |  |
57 Trials |
|
57 Trials |  |
3617 News |  |
| 12345678910111213...4041» |
- | Januvia (sitagliptin) / Merck (MSD)
Journal: Electrochemical Synthesis of a Sitagliptin Precursor. (Pubmed Central) - Apr 24, 2024
These sitagliptin-analogue precursors could potentially interact with the DPP4 enzyme. A full synthesis based on our new reaction pathway provided sitagliptin in an overall yield of 33%.
- | Januvia (sitagliptin) / Merck (MSD)
Journal: Functional roles of CD26/DPP4 in lipopolysaccharide-induced lung injury. (Pubmed Central) - Apr 24, 2024
We previously reported that DPP4 inhibition by sitagliptin attenuates lipopolysaccharide (LPS)-induced lung injury in mice...In summary, this study demonstrated that genetic deficiency of Dpp4 attenuates inflammatory responses but not permeability in LPS-induced lung injury in mice, potentially through differential functional roles of CD26/DPP4 expression in resident cellular components of the lung. CD26/DPP4 may be a potential therapeutic target for ARDS and warrants further exploration to precisely identify the multiple functional effects of CD26/DPP4 in ARDS pathophysiology.
- | Januvia (sitagliptin) / Merck (MSD)
Journal: Prediction of glycosylated hemoglobin level in patients with cardiovascular diseases and type 2 diabetes mellitus with respect to anti-diabetic medication. (Pubmed Central) - Apr 23, 2024
Patients were prescribed metformin. One group (n=60) additionally was taking sitagliptin...We tested the best models on the external testing set and got R2
- | Januvia (sitagliptin) / Merck (MSD)
Journal: Miniature mass spectrometer-based point-of-care assay for quantification of metformin and sitagliptin in human blood and urine. (Pubmed Central) - Apr 20, 2024
The MS/MS responses exhibited good linear relationship with concentration, with relative standard deviations (RSDs) below 25%. It has the potential to provide immediate treatment feedback and decision support for patients and healthcare professionals in clinical practice.
- || Nesina (alogliptin) / Takeda, Januvia (sitagliptin) / Merck (MSD)
P4 data, Journal: Comprehensive safety profile of dipeptidyl peptidase-4 inhibitors: a post-marketing study based on FAERS database using signal detection algorithms. (Pubmed Central) - Apr 16, 2024
Several significant disproportionality signals were observed with DPP-4 inhibitors. However, clinicians have to consider the comorbidities and concomitant drugs while prescribing these drugs.
- Stelara (ustekinumab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Januvia (sitagliptin) / Merck (MSD)
Evaluating Healthcare Costs and Demographics of Medicare Part D Beneficiaries Impacted by First Top 10 Drugs Selected for Price Negotiations Under the Inflation Reduction Act (IRA) () - Apr 14, 2024 - Abstract #ISPOR2024ISPOR_2544;
Lower negotiated prices would lower beneficiaries' drug costs and potentially increase access to the selected drug. Black, Hispanic, and Asian LIS beneficiaries will be disproportionately impacted by the price negotiations.
- | Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Januvia (sitagliptin) / Merck (MSD)
Journal: Comparative Study on Efficacy of Empagliflozin Versus Sitagliptin, as an Add-on Therapy to Metformin in Type 2 Diabetic Patients. (Pubmed Central) - Apr 10, 2024
There were 57.67% men and 42.33% females. "The mean reduction in HbA1c from baseline in Group A was -0.65
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Januvia (sitagliptin) / Merck (MSD)
Journal: Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients. (Pubmed Central) - Apr 9, 2024
These results suggest gliptins should be prescribed with caution to patients with type 2 diabetes with coexisting Alzheimer's and other dementias, or patients receiving long-term use of thiazides and loop diuretics. The use of sitagliptin over linagliptin and vildagliptin should be preferred in these patients.
- What will be the impact on minority groups in 2026 when Medicare Part D price cuts take effect? () - Apr 9, 2024 - Abstract #AMCP2024AMCP_188;
All 3 groups have higher use than Medicare enrollees overall, for use of selected diabetes drugs, Farxiga (dapagliflozin), Januvia (sitagliptin), and Jardiance (empagliflozin). Black and Latino enrollees also index higher for use of Novolog/Fiasp (insu- lin aspart)...Latino people
- | Januvia (sitagliptin) / Merck (MSD)
Journal: Enantioselective Synthesis of (R)-Sitagliptin via Phase-Transfer Catalytic aza-Michael Addition. (Pubmed Central) - Apr 8, 2024
Hydrolysis and amide coupling were then employed to construct the amide moiety. Further deprotections were performed to complete the synthesis of (R)-sitagliptin (7 steps, 41%, 96% ee).
- || Januvia (sitagliptin) / Merck (MSD)
Clinical, Journal: Efficacy and safety of sitagliptin with basal-plus insulin regimen versus insulin alone in non-critically ill hospitalized patients with type 2 diabetes: SITA-PLUS hospital trial. (Pubmed Central) - Apr 6, 2024
P4
Further deprotections were performed to complete the synthesis of (R)-sitagliptin (7 steps, 41%, 96% ee). For inpatients with T2D and hyperglycemia, the sitagliptin and BP regimen combination is safe and more effective than insulin therapy alone.
- | Januvia (sitagliptin) / Merck (MSD)
Journal: Cyclosporine-induced kidney damage was halted by sitagliptin and hesperidin via increasing Nrf2 and suppressing TNF-?, NF-?B, and Bax. (Pubmed Central) - Apr 2, 2024
Hesperidin or sitagliptin could protect the kidney against CsA through the mitigation of oxidative stress, apoptosis, and inflammation. Sitagliptin proved to be more
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Januvia (sitagliptin) / Merck (MSD)
Journal, HEOR, Cost-effectiveness, Cost effectiveness: The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China. (Pubmed Central) - Apr 2, 2024
Sitagliptin proved to be more Once-weekly semaglutide may represent a cost-effective add-on therapy alternative to sitagliptin for type 2 diabetes patients inadequately controlled on metformin in China.
- | Januvia (sitagliptin) / Merck (MSD)
Preclinical, Journal: DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson's disease. (Pubmed Central) - Apr 2, 2024
Combined GLP-1 and GIP receptor activation in neuronal cultures resulted in neurotrophic/neuroprotective actions superior to single agonists alone. In conclusion, these studies support further evaluation of the repurposing of clinically approved gliptins as a treatment strategy for PD.
- | navitoclax (ABT 263) / AbbVie, Januvia (sitagliptin) / Merck (MSD)
Journal: Selective targeting of dipeptidyl-peptidase 4 (DPP-4) positive senescent chondrocyte ameliorates osteoarthritis progression. (Pubmed Central) - Apr 1, 2024
In conclusion, these studies support further evaluation of the repurposing of clinically approved gliptins as a treatment strategy for PD. To assess in
- || Januvia (sitagliptin) / Merck (MSD)
PK/PD data, Journal: Safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modeling of cetagliptin in patients with type 2 diabetes mellitus. (Pubmed Central) - Mar 30, 2024
The subjects were randomly assigned to receive either cetagliptin (50 mg or 100 mg), placebo, or sitagliptin (100 mg) once daily for 14 days...Cetagliptin was well tolerated, inhibited plasma DPP-4 activity, increased plasma active GLP-1 levels, and exhibited a certain trend of glucose-lowering effect in patients with T2DM. The established population PK/PD model adequately described the PK and PD characteristics of cetagliptin.
- | Januvia (sitagliptin) / Merck (MSD)
Journal: Sitagliptin elevates plasma and CSF incretin levels following oral administration to nonhuman primates: relevance for neurodegenerative disorders. (Pubmed Central) - Mar 27, 2024
Additional cellular studies evaluating human SH-SY5Y and primary rat ventral mesencephalic cultures challenged with 6-hydroxydopamine, established cellular models of PD, demonstrated that joint treatment with GLP-1?+?GIP mitigated cell death, particularly when combined with DPP-4 inhibition to maintain incretin levels. In conclusion, this study provides a supportive translational step towards the clinical evaluation of sitagliptin in PD and other neurodegenerative disorders for which aging, similarly, is the greatest risk factor.
- || metformin / Generic mfg.
Review, Journal: A comprehensive review on potential drug-drug interactions of proton pump inhibitors with antidiabetic drugs metformin and DPP-4 inhibitors. (Pubmed Central) - Mar 18, 2024
This review article mainly focused on evaluating the potential drug-drug interactions (DDIs) between PPIs (i.e. esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole) with metformin and PPIs with DPP-4 inhibitors...To achieve the greatest therapeutic impact with the fewest side effects, careful dose control of these drugs is required. So, more extensive research on both human and animal subjects are needed to ascertain the veracity of this hypothesis.
- | Januvia (sitagliptin) / Merck (MSD)
Journal, Stroma: Effects of sitagliptin activation of the stromal cell-derived factor-1/CXC chemokine receptor 4 signaling pathway on the proliferation, apoptosis, inflammation, and osteogenic differentiation of human periodontal ligament stem cells induced by lipopolysaccharide. (Pubmed Central) - Mar 17, 2024
Sitagliptin may promote the proliferation and osteogenic differentiation of hPDLSCs in LPS-induced inflammatory microenvironment by activating the SDF-1/CXCR4 signaling pathway. Furthermore, it inhibited the apoptosis and inflammatory response of hPDLSCs.
- | Januvia (sitagliptin) / Merck (MSD)
Journal: DPP-4 inhibitor sitagliptin treatment results in altered myocardial metabolic proteome and oxidative phosphorylation in a swine model of chronic myocardial ischemia. (Pubmed Central) - Mar 17, 2024
Sitagliptin treatment resulted in a trend towards decreased cardiac index and decreased expression of proteins involved in OXPHOS, FAO, and myocardial contraction in both ischemic and non-ischemic swine myocardium. These metabolic and functional changes may provide some mechanistic evidence for outcomes seen in clinical studies.
- | Januvia (sitagliptin) / Merck (MSD)
Journal: Analytical quality by design approach for the development of high-performance liquid chromatography method for simultaneous analysis of metformin and sitagliptin in the presence of major degradation products. (Pubmed Central) - Mar 15, 2024
These metabolic and functional changes may provide some mechanistic evidence for outcomes seen in clinical studies. The linearity ranges of 25-250
- | Januvia (sitagliptin) / Merck (MSD)
Journal: Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells. (Pubmed Central) - Mar 13, 2024
Our findings indicate that sitagliptin-mediated DPP4 inhibition promotes antitumor immune response by augmenting cDC1 functions. These data suggest that sitagliptin can be repurposed as an antitumor drug targeting DC, which provides a potential strategy for cancer immunotherapy.
- Januvia (sitagliptin) / Merck (MSD)
Assessing the effects of sitagliptin and risperidone on locomotor activity, inflammatory responses, and lipid peroxidation in a mouse model of induced autism | Poster Board #515 (In-person; Poster Board #515; Hall C (Ernest N. Morial Convention Center)) - Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_9291;
These findings highlight the potential promise of sitagliptin as a therapeutic intervention for individuals with ASD. Its ability to alleviate oxidative stress, neuro-inflammation, and behavioral abnormalities, coupled with its strong anxiolytic and antioxidant properties, positions sitagliptin as a compelling candidate for further exploration in the quest for effective ASD treatments.
- Stelara (ustekinumab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Januvia (sitagliptin) / Merck (MSD)
Evaluating Healthcare Costs and Demographics of Medicare Part D Beneficiaries Impacted by First Top 10 Drugs Selected for Price Negotiations Under the Inflation Reduction Act (IRA) () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2177;
Lower negotiated prices would lower beneficiaries' drug costs and potentially increase access to the selected drug. Black, Hispanic, and Asian LIS beneficiaries will be disproportionately impacted by the price negotiations.
- Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
Assessing Cost-Savings From the Inflation Reduction Act in Louisiana Medicare Beneficiaries Due to Diabetes Medications () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1645;
Black, Hispanic, and Asian LIS beneficiaries will be disproportionately impacted by the price negotiations. Using the Part D Events file, the number of patients taking a drug, total costs, and total amount patients paid were extracted for Empagliflozin, Sitagliptin, and Dapagliflozin
- | Natrecor (nesiritide) / J&J, Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, Januvia (sitagliptin) / Merck (MSD)
Trial completion date, Trial primary completion date: Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1 (clinicaltrials.gov) - Mar 5, 2024
P4, N=32, Active, not recruiting, Sponsor: Vanderbilt University Medical Center
Using the Part D Events file, the number of patients taking a drug, total costs, and total amount patients paid were extracted for Empagliflozin, Sitagliptin, and Dapagliflozin Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
- | Victoza (liraglutide) / Novo Nordisk, Januvia (sitagliptin) / Merck (MSD)
Journal, HEOR: The incidence of retinopathy in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness study (GRADE). (Pubmed Central) - Mar 4, 2024
P3
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jul 2024 --> Jul 2025 Based on self-report in the GRADE diabetes study, cumulative incidence of retinopathy was low over 5
- | Januvia (sitagliptin) / Merck (MSD), Imbruvica (ibrutinib) / AbbVie, J&J
Reimbursement, US reimbursement, Journal, Medicare: SOCIODEMOGRAHIC AND SPENDING CHARACTERISTICS OF MEDICARE BENEFICIARIES TAKING PRESCRIPTION DRUGS SUBJECT TO PRICE NEGOTIATIONS. (Pubmed Central) - Mar 4, 2024
Negotiations could reduce out-of-pocket costs through reduced coinsurance payments for this group, which is older and has more chronic conditions compared to beneficiaries not taking negotiated drugs. Part D plan design, spending, and utilization changes should be monitored post-negotiation to determine if further solutions are needed to lower out-of-pocket costs for this group.
- || Victoza (liraglutide) / Novo Nordisk, Januvia (sitagliptin) / Merck (MSD)
Clinical, Journal, HEOR: Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): A Randomized Clinical Trial. (Pubmed Central) - Feb 28, 2024
Liraglutide also reduced diabetes distress at 1 year. Results can inform treatment decisions for adults with early T2DM.
- | Ansimar (doxofylline) / ICE GROUP, Alitair Pharma, Januvia (sitagliptin) / Merck (MSD)
Journal: Biochemical evaluation and ligand binding studies on glycerophosphodiester phosphodiesterase from Staphylococcus aureus using STD-NMR spectroscopy and molecular docking analysis. (Pubmed Central) - Feb 19, 2024
Results can inform treatment decisions for adults with early T2DM. In this study, competent E. coli BL21(DE3)pLysS expression cells were used to express the GDPD enzyme from vancomycin-resistant Staphylococcus aureus (VRSA), which was then purified using size exclusion and anion exchange chromatography...Out of 79 drugs, 13 drugs, including tenofovir (1), adenosine (2), clioquinol (11), bromazepam (12), lamotrigine (13), sulfadiazine (14), azathioprine (15), nicotine (16), sitagliptin PO4 (17), doxofylline (18), clindamycin phosphate (19), gentamycin sulphate (20), and ceftriaxone sodium (21) revealed varying degrees of inhibitory potential with IC50 values in the range of 400
- ||| Victoza (liraglutide) / Novo Nordisk, Byetta (exenatide) / AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
Journal, Adverse events, Real-world evidence, Real-world: Drug-induced Acute Pancreatitis: A Real-world Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database. (Pubmed Central) - Feb 19, 2024
According to the positive-negative distribution of ADR signal for drug classes, the drug class with the greatest number of positive drugs was antineoplastic agents. In this study, we provided the current comprehensive landscape of AP culprit-drugs from the pharmacovigilance perspective, which can provide reference information for clinical practice.
- | Victoza (liraglutide) / Novo Nordisk, Januvia (sitagliptin) / Merck (MSD)
Journal, HEOR: Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study). (Pubmed Central) - Feb 12, 2024
P3
This comparative effectiveness study of a contemporary cohort of adults with type 2 diabetes, largely without established cardiovascular disease, suggests that liraglutide treatment may reduce the risk of cardiovascular events in patients at relatively low risk compared with other commonly used glucose-lowering medications. URL: https://www.clinicaltrials.gov; Unique identifier: NCT01794143.
- | Januvia (sitagliptin) / Merck (MSD)
Preclinical, Journal: Attenuation of acrylamide-induced neurotoxicity by supplementation of sitagliptin in Wistar rats. (Pubmed Central) - Feb 9, 2024
Sitagliptin disclosed preventive and therapeutic effects on ACR neurotoxicity. Sitagliptin possesses antioxidant, anti-inflammatory, and anti-apoptotic properties and inhibits CR neurotoxicity in rats.
- | Januvia (sitagliptin) / Merck (MSD)
Journal: Glp-1 Mimetics and Autophagy in Diabetic Milieu: State-of-the-Art. (Pubmed Central) - Feb 1, 2024
However, some evidence suggests that they can provide extra glycemic benefits by modulating autophagy, although there is no complete understanding of this mechanism and its underlying molecular pathways. Hence, in the current review, we aimed to provide new insights on the possible impact of Glp-1 mimetics on autophagy and consequent benefits as well as mediating pathways.
- | Januvia (sitagliptin) / Merck (MSD)
Preclinical, Journal: In vivo inhibition of dipeptidyl peptidase 4 allows measurement of GLP-1 secretion in mice. (Pubmed Central) - Jan 31, 2024
We then administered saline (control), or a DPP-4 inhibitor (valine pyrrolidide or sitagliptin) with or without a NEP-inhibitor (sacubitril) 30 minutes before the OGTT...We conclude that reliable measurement of GLP-1 secretion is not possible in mice in vivo with commercially available sandwich ELISA kits, unless degradation is prevented by inhibition of DPP-4 and perhaps neprilysin. The described approach allows improved estimates of GLP-1 secretion for future studies, although it is a limitation that these inhibitors additionally influence levels of insulin and glucagon.
- | Januvia (sitagliptin) / Merck (MSD)
Preclinical, Journal, Metastases: Synthesis, characterization and in-vitro cytotoxic potential of sitagliptin phosphate nanoparticles against advanced breast cancer cell line - MCF-7. (Pubmed Central) - Jan 28, 2024
The SIT-CS-NPs had a 120-hour release efficiency of up to 80%. This suggests that these nanoparticles could cure hepatocellular carcinoma, specifically MCF-7 cell lines.
- Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Januvia (sitagliptin) / Merck (MSD)
MEDICARE UTILIZATION AND SPENDING ON THE 10 DRUGS SELECTED FOR NEGOTIATION UNDER THE INFLATION REDUCTION ACT (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_3907;
Among the 10 drugs initially selected for negotiation under the IRA, medications for cardiovascular disease have the most rapid increase in utilization. Diabetes and cardiovascular medications also make up the vast majority of spending on the 10 drugs, led by apixaban, rivaroxaban and sitagliptin.
- | Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Januvia (sitagliptin) / Merck (MSD)
Journal: Network Proteins of Human Sortilin1, Its Expression and Targetability Using Lycopene. (Pubmed Central) - Jan 23, 2024
IGF2R and GRN are relevant networks of SORT1, regulating tissue fibrosis or the microcalcification process. SORT1 can be targeted using currently approved small-molecule therapeutics (empagliflozin and sitagliptin) or widely used nutraceuticals (lycopene), which should be evaluated in a randomised clinical trial to assess their efficacy in reducing the cardiac/vascular microcalcification process.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Januvia (sitagliptin) / Merck (MSD)
Journal: Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes. (Pubmed Central) - Jan 18, 2024
P3
SORT1 can be targeted using currently approved small-molecule therapeutics (empagliflozin and sitagliptin) or widely used nutraceuticals (lycopene), which should be evaluated in a randomised clinical trial to assess their efficacy in reducing the cardiac/vascular microcalcification process. This analysis confirms efficacy and safety of OW semaglutide (0.5 and 1.0 mg) in a Korean population with T2D.
- | Januvia (sitagliptin) / Merck (MSD)
Preclinical, Journal: Preclinical Repurposing of Sitagliptin as a Drug Candidate for Colorectal Cancer by Targeting CD24/CTNNB1/SOX4-Centered Signaling Hub. (Pubmed Central) - Jan 15, 2024
Using a molecular docking approach, we demonstrated that sitagliptin targeted CD24/SOX4-centered signaling molecules with high affinity. In vitro experimental data showed that sitagliptin treatment suppressed CRC tumorigenic properties and worked in synergy with 5FU and this study thus provided preclinical evidence to support the alternative use of sitagliptin for treating CRC.
- | Tenelia (teneligliptin) / Daiichi Sankyo, Mitsubishi Tanabe
Retrospective data, Review, Journal: Efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis. (Pubmed Central) - Jan 12, 2024
Twenty milligrams or 40 mg per day was the optimal dosage regimen of teneligliptin. The results of this study will provide important evidence-based basis for rational use of teneligliptin and clinical decision-making of T2DM medication.
- | Januvia (sitagliptin) / Merck (MSD)
Journal: A case of anti-laminin ?1 (p200) pemphigoid developed after dipeptidyl peptidase-4 inhibitor administration. (Pubmed Central) - Jan 12, 2024
These results indicated that this patient was diagnosed with anti-laminin ?1 (p200) pemphigoid developed after DPP-4i administration. Although reports of DPP-4i-related bullous pemphigoid have accumulated, cases of anti-laminin ?1 (p200) pemphigoid developed after DPP-4i administration are rarely reported.
- | Bilessglu (chiglitazar) / Chipscreen
Journal: Plasma proteome profiling reveals the therapeutic effects of the PPAR pan-agonist chiglitazar on insulin sensitivity, lipid metabolism, and inflammation in type 2 diabetes. (Pubmed Central) - Jan 10, 2024
Our study indicated that 13 proteins were associated with chiglitazar treatment in T2D patients, including 10 up-regulated proteins (SHBG, TF, APOA2, APOD, GSN, MBL2, CFD, PGLYRP2, A2M, and APOA1) and 3 down-regulated proteins (PRG4, FETUB, and C2) after treatment, which were implicated in the regulation of insulin sensitivity, lipid metabolism, and inflammation response. Our study provides insight into the response of chiglitazar treatment from a proteome perspective and demonstrates the multi-faceted effects of chiglitazar in T2D patients, which will help the clinical application of chiglitazar and further study of its action mechanism.
- | Victoza (liraglutide) / Novo Nordisk, Januvia (sitagliptin) / Merck (MSD)
Journal, HEOR: Comparative Effects of Randomized Second-line Therapy for Type 2 Diabetes on a Composite Outcome Incorporating Glycemic Control, Body Weight, and Hypoglycemia: An Analysis of Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). (Pubmed Central) - Jan 9, 2024
Among participants treated with common second-line drug classes for type 2 diabetes, the liraglutide group had the lowest and glimepiride the highest risk of reaching a composite outcome encompassing glycemic deterioration, weight gain, and hypoglycemia. These findings may inform decision-making regarding type 2 diabetes therapy.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Greater time spent with HbA1c?less than?7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies. (Pubmed Central) - Jan 9, 2024
These findings may inform decision-making regarding type 2 diabetes therapy. Oral semaglutide 7 and 14?mg resulted in greater time spent with HbA1c?less than?7.0%, and a greater likelihood of achieving and maintaining HbA1c less than?7.0% versus oral comparators.
- | Januvia (sitagliptin) / Merck (MSD)
Preclinical, Journal: Role of the integrin-linked kinase/TGF-?/SMAD pathway in sitagliptin-mediated cardioprotective effects in a rat model of diabetic cardiomyopathy. (Pubmed Central) - Jan 8, 2024
Sitagliptin could afford cardioprotective effects for the first time by altering ILK-associated TGF-?/SMAD signaling pathways. Thus, sitagliptin may be a promising therapeutic target for the prevention of diabetic cardiomyopathy.
- | Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Januvia (sitagliptin) / Merck (MSD)
Enrollment open: Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia (clinicaltrials.gov) - Jan 4, 2024
P=N/A, N=220, Recruiting, Sponsor: Medanta, The Medicity, India
Thus, sitagliptin may be a promising therapeutic target for the prevention of diabetic cardiomyopathy. Not yet recruiting --> Recruiting
- | Tenelia (teneligliptin) / Daiichi Sankyo, Mitsubishi Tanabe
Observational data, Journal: Comparison of teneligliptin and other gliptin-based regimens in addressing insulin resistance and glycemic control in type 2 diabetic patients: a cross-sectional study. (Pubmed Central) - Jan 3, 2024
Teneligliptin seems to be cost-effective and safer option in T2DM subjects who were not adequately controlled with metformin and sulfonylureas. However, further prospective studies are needed.
- | Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Januvia (sitagliptin) / Merck (MSD)
New trial: Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia (clinicaltrials.gov) - Jan 1, 2024
P=N/A, N=220, Not yet recruiting, Sponsor: Medanta, The Medicity, India
- | Januvia (sitagliptin) / Merck (MSD)
Journal: miR-23b-3p Ameliorates LPS-Induced Pulmonary Fibrosis by Inhibiting EndMT via DPP4 Inhibition. (Pubmed Central) - Dec 27, 2023
In our mouse model of LPS-induced pulmonary fibrosis, miR-23b-3p and a DPP4 inhibitor (sitagliptin) individually alleviated LPS-induced EndMT progression and pulmonary fibrosis, and their combined use achieved the strongest remission effect. To sum up, miR-23b-3p alleviates EndMT in pulmonary fibrosis by inhibiting the expression of DPP4.